Advertisement
UK markets close in 25 minutes

  • FTSE 100

    8,174.68
    +53.44 (+0.66%)
     

  • FTSE 250

    19,998.95
    +72.36 (+0.36%)
     

  • AIM

    767.50
    +2.52 (+0.33%)
     

  • GBP/EUR

    1.1682
    -0.0002 (-0.02%)
     

  • GBP/USD

    1.2487
    -0.0037 (-0.30%)
     

  • Bitcoin GBP

    47,335.25
    +1,440.68 (+3.14%)
     

  • CMC Crypto 200

    1,273.03
    +2.29 (+0.18%)
     

  • S&P 500

    5,038.92
    +20.53 (+0.41%)
     

  • DOW

    38,086.19
    +182.90 (+0.48%)
     

  • CRUDE OIL

    78.81
    -0.19 (-0.24%)
     

  • GOLD FUTURES

    2,310.90
    -0.10 (-0.00%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,207.13
    +444.10 (+2.50%)
     

  • DAX

    17,912.00
    -20.17 (-0.11%)
     

  • CAC 40

    7,928.65
    -56.28 (-0.70%)
     
Money:

Best UK mortgage deals of the week

The cheapest home loans available now

UPDATE 1-Elanco appoints two directors after settling with activist Ancora

Reuters
·1-min read

(Adds background in paragraphs 2-4)

April 1 (Reuters) - Elanco Animal Health said on Monday that it had appointed two new directors to its board after reaching an agreement with activist investor Ancora Holdings but stopped short of naming a new CEO.

The company that makes medicines and vaccinations for pets and livestock said it has added Kathy Turner and Craig Wallace to the board of directors.

The investment firm, which holds about a 2% stake in the company, had said in

February

that it wanted four board seats at Elanco and to replace CEO Jeffrey Simmons over "poor performance."

Craig Wallace is a former senior executive at French animal health company Ceva Santé Animale, and Kathy Turner has previously been a senior executive at animal healthcare company IDEXX Laboratories.

(Reporting by Sneha S K in Bengaluru; Editing by Tasim Zahid)